Latest news
TLX591 Antibody-Based Lutetium-177 PSMA Therapy in Metastatic CRPC - Pedro Barata - UroTodayUroToday · Thu, 06 Aug 2026 05:07:45 GMTFDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer - Targeted OncologyTargeted Oncology · Fri, 31 Jul 2026 21:11:29 GMTFDA OKs Lutetium Lu 177 Vipivotide Tetraxetan in Metastatic Prostate Cancer - CancerNetworkCancerNetwork · Fri, 31 Jul 2026 20:58:12 GMT